T2w images with overlays of lesion boundaries, DWI-derived ADC, DCE-derived 𝐾𝑡𝑟𝑎𝑛𝑠, and CDI𝑠 for six patient cases. (a, b) Two patients with csPCa in the PZ. (c, d) Two patients with csPCa in the TZ. (e) A patient with csPCa in the PZ and insPCa in the TZ. (f) A patient with csPCa in the AS and insPCa in the PZ.

March 28, 2022 — A new form of magnetic resonance imaging (MRI) that makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time.

The innovation, developed by researchers at the University of Waterloo, creates images in which cancerous tissue appears to light up compared to healthy tissue, making it easier to see.

"Our studies show this new technology has promising potential to improve cancer screening, prognosis and treatment planning," said Alexander Wong, Canada Research Chair in Artificial Intelligence and Medical Imaging and a professor of systems design engineering at Waterloo.

Irregular packing of cells leads to differences in the way water molecules move in cancerous tissue compared to healthy tissue. The new technology, called synthetic correlated diffusion imaging, highlights these differences by capturing, synthesizing and mixing MRI signals at different gradient pulse strengths and timings.

In the largest study of its kind, the researchers collaborated with medical experts at the Lunenfeld-Tanenbaum Research Institute, several Toronto hospitals and the Ontario Institute for Cancer Research to apply the technology to a cohort of 200 patients with prostate cancer.

Compared to standard MRI techniques, synthetic correlated diffusion imaging was better at delineating significant cancerous tissue, making it a potentially powerful tool for doctors and radiologists.

"Prostate cancer is the second most common cancer in men worldwide and the most frequently diagnosed cancer among men in more developed countries," said Wong, also a director of the Vision and Image Processing (VIP) Lab at Waterloo. "That's why we targeted it first in our research.

"We also have very promising results for breast cancer screening, detection, and treatment planning. This could be a game-changer for many kinds of cancer imaging and clinical decision support."

The core research team also included Hayden Gunraj and Vignesh Sivan, engineering graduate students at Waterloo, and Dr. Masoom Haider of the Lunenfeld-Tanenbaum Research Institute. 

Their paper, Synthetic correlated diffusion imaging hyperintensity delineates clinically significant prostate cancer, appears in the journal Scientific Reports.

For more information: www.uwaterloo.ca


Related Content

News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | PET Imaging

April 24, 2024 — A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare ...

Time April 24, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group, led by authors at the University of Toronto, have developed an approach for ...

Time April 23, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Subscribe Now